BRRGF (Oncoinvent ASA) Tariff Resilience Score: 0/10 (As of Jul. 13, 2026)


BRRGF Oncoinvent ASA BRRGF
37 GF Score
Price $97.09
GF Value $1,432.14
! 4 Warning Signs
View Full Analysis

What is Oncoinvent ASA Tariff Resilience Score?

Oncoinvent ASA has the Tariff Resilience Score of 0, which implies that the company might have .

Oncoinvent ASA has

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Oncoinvent ASA might have .

Oncoinvent ASA  (OTCPK:BRRGF) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Oncoinvent ASA Tariff Resilience Score Related Terms

BRRGF
37GF Score
Oncoinvent ASA BRRGF
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Oncoinvent ASA (BRRGF) Overvalued in 2026?

Based on GuruFocus' analysis, Oncoinvent ASA stock appears to be undervalued. The current stock price of $97.09 is trading 93.2% below its estimated GF Value™ of $1,432.14.

Key valuation signals for BRRGF:

  • Tariff Resilience Score: 0
  • GF Value™: $1,432.14 vs. price of $97.09 (93.2% below fair value)
  • GF Score™: 37/100 with 4 warning signs

No single metric tells the full story. See the BRRGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Oncoinvent ASA Business Description

Address Gullhaugveien 7, Oslo, NOR, 0484
Oncoinvent ASA is a clinical-stage biotechnology company developing novel radiopharmaceutical therapies against cancer. Its key product candidate is Radspherin, a receptor-independent alpha radiation therapy that leverages the anatomy of the abdominal cavity to destroy residual micrometastases using a single, localized dose of alpha radiation. Radspherin is currently in clinical development in two indications: peritoneal metastasis from ovarian and colorectal cancer, but it is also relevant for treating peritoneal metastasis from other cancer types and potentially metastatic cancer in other body cavities. Geographically, the company operates in Norway.
37GF Score

Get the complete analysis for BRRGF

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$97.09
Price
$1,432.14
GF Value